Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre I Karakiewicz

Showing results (31-40 of 1,457) with videos related to

Pageof 146
Sort By:
European Urology|December 21, 2007
The search for better prognostic factors for men treated for localized prostate cancer continuesPierre I Karakiewicz, Nazareno Suardi, Shahrokh F Shariat
European Urology|March 11, 2008
Rebuttal from authors re: James W.F. Catto. More nomograms or better evidence of efficacy: what do we need in urologic oncology? Eur Urol 2008;54:11-12Shahrokh F Shariat, Vitaly Margulis, Pierre I Karakiewicz
The Journal of Urology|September 28, 2011
Editorial commentMaxine Sun, Quoc-Dien Trinh, Pierre I Karakiewicz
Current Opinion in Urology|July 2, 2010
Factors affecting outcome in renal cell carcinomaMaxine Sun, Shahrokh F Shariat, Pierre I Karakiewicz
BJU International|August 30, 2012
The case for partial nephrectomy: action is requiredMaxine Sun, Quoc-Dien Trinh, Pierre I Karakiewicz
European Urology|August 6, 2013
Reply to Hiten D. Patel and Mohamad E. Allaf's letter to the editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034Maxine Sun, Pierre I Karakiewicz, Quoc-Dien Trinh
European Urology|October 28, 2008
Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigatorsShahrokh F Shariat, Christian Bolenz, Pierre I Karakiewicz
The Lancet. Oncology|November 3, 2012
Conditional survival of patients with metastatic renal-cell carcinomaMaxine Sun, Quoc-Dien Trinh, Pierre I Karakiewicz
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 31, 2010
Should all men having a radical prostatectomy have a pelvic lymph node dissection? NoFiras Abdollah, Maxine Sun, Rodolphe Thuret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
PISCES: a horoscope for first-line targeted therapy of metastatic renal cell carcinomaMaxine Sun, Alessandro Larcher, Jonas Schiffmann, et al.
Pageof 146

Showing results (31-40 of 1,457) with videos related to

Sort By:
Pageof 146
European Urology|December 21, 2007
The search for better prognostic factors for men treated for localized prostate cancer continuesPierre I Karakiewicz, Nazareno Suardi, Shahrokh F Shariat
European Urology|March 11, 2008
Rebuttal from authors re: James W.F. Catto. More nomograms or better evidence of efficacy: what do we need in urologic oncology? Eur Urol 2008;54:11-12Shahrokh F Shariat, Vitaly Margulis, Pierre I Karakiewicz
The Journal of Urology|September 28, 2011
Editorial commentMaxine Sun, Quoc-Dien Trinh, Pierre I Karakiewicz
Current Opinion in Urology|July 2, 2010
Factors affecting outcome in renal cell carcinomaMaxine Sun, Shahrokh F Shariat, Pierre I Karakiewicz
BJU International|August 30, 2012
The case for partial nephrectomy: action is requiredMaxine Sun, Quoc-Dien Trinh, Pierre I Karakiewicz
European Urology|August 6, 2013
Reply to Hiten D. Patel and Mohamad E. Allaf's letter to the editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034Maxine Sun, Pierre I Karakiewicz, Quoc-Dien Trinh
European Urology|October 28, 2008
Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigatorsShahrokh F Shariat, Christian Bolenz, Pierre I Karakiewicz
The Lancet. Oncology|November 3, 2012
Conditional survival of patients with metastatic renal-cell carcinomaMaxine Sun, Quoc-Dien Trinh, Pierre I Karakiewicz
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 31, 2010
Should all men having a radical prostatectomy have a pelvic lymph node dissection? NoFiras Abdollah, Maxine Sun, Rodolphe Thuret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
PISCES: a horoscope for first-line targeted therapy of metastatic renal cell carcinomaMaxine Sun, Alessandro Larcher, Jonas Schiffmann, et al.
Pageof 146